J Obes Metab Syndr.  2020 Jun;29(2):99-109. 10.7570/jomes20010.

Current Long-Term Pharmacotherapies for the Management of Obesity

Affiliations
  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea
  • 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Sun Medical Center, Daejeon, Korea
  • 3Department of Family Medicine, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea
  • 4Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
  • 5Department of Family Practice and Community Health, Ajou University Medical Center, Suwon, Korea
  • 6Department of Psychiatry, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea
  • 7Department of Family Medicine, Korea University College of Medicine, Seoul, Korea
  • 8Department of Family Medicine, Eulji Hospital, Eulji University School of Medicine, Seoul, Korea
  • 9Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
  • 10Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea
  • 11Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea
  • 12Department of Pediatrics, National Medical Center, Seoul, Korea
  • 13Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
  • 14Central St’ Mary’s Clinic Internal Medicine, Seoul, Korea
  • 15Division of Endocrinology and Metabolism, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea
  • 16Department of Pediatrics, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea
  • 17Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea
  • 18Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, Bucheon, Korea

Abstract

Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a body mass index ≥25 kg/m2. Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualized treatment of obesity.

Keyword

Obesity; Orlistat; Lorcaserin; Liraglutide; Naltrexone/bupropion extended-release; Phentermine/topiramate extended-release
Full Text Links
  • JOMES
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr